Myelofibrosis: Symptom Burden, Risk Stratification, and Novel Treatments – Enduring Webcast

Description

Program Description

---

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis. The considerable heterogeneity of MF translates into a wide range of outcomes. Given this heterogeneity, risk stratification for individualized management becomes essential in disease treatment. Treatment of MF according to the NCCN treatment guidelines is dependent on several factors—risk stratification, symptom burden, and eligibility for different treatment options; however, the simplified recommendation is to initiate treatment in any patient with MF experiencing symptoms that impact their QoL—specifically, general systemic symptoms or symptomatic splenomegaly.

Intended Audience

---

Hematologists/ oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals caring for myelofibrosis

Commercial Supporter

---

This activity is supported by an educational grant from CTI Biopharma Corp., a Sobi company.